Cytosorbents Corp (CTSO) stock
CTSONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$4.52−0.33 (-6.80%)
Close on Nov 17, 2026Market cap $284.05MP/E –Yield –
Cytosorbents operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Cytosorbents's operating income for the twelve months ending Jun 30, 2026 was -$12.93M. For fiscal 2025 it was -$14.75M. The highest annual figure on record is -$2.82M in fiscal 2010.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$14.75M | – |
| FY2024 | Dec 31, 2024 | -$16.45M | – |
| FY2023 | Dec 31, 2023 | -$31.95M | – |
| FY2022 | Dec 31, 2022 | -$31.52M | – |
| FY2021 | Dec 31, 2021 | -$22.74M | – |
| FY2020 | Dec 31, 2020 | -$10.37M | – |
| FY2019 | Dec 31, 2019 | -$18.97M | – |
| FY2018 | Dec 31, 2018 | -$15.58M | – |
| FY2017 | Dec 31, 2017 | -$9.84M | – |
| FY2016 | Dec 31, 2016 | -$11.49M | – |
| FY2015 | Dec 31, 2015 | -$9.30M | – |
| FY2014 | Dec 31, 2014 | -$6.89M | – |
| FY2013 | Dec 31, 2013 | -$4.71M | – |
| FY2012 | Dec 31, 2012 | -$3.49M | – |
| FY2011 | Dec 31, 2011 | -$4.44M | – |
| FY2010 | Dec 31, 2010 | -$2.82M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$2.64M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.04M | – |
| Q4 FY2025 | Dec 31, 2025 | -$4.39M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.86M | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.62M | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.89M | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.40M | – |
| Q3 FY2024 | Sep 30, 2024 | -$4.83M | – |
| Q2 FY2024 | Jun 30, 2024 | -$3.57M | – |
| Q1 FY2024 | Mar 31, 2024 | -$4.66M | – |
| Q4 FY2023 | Dec 31, 2023 | -$9.41M | – |
| Q3 FY2023 | Sep 30, 2023 | -$7.35M | – |
| Q2 FY2023 | Jun 30, 2023 | -$6.56M | – |
| Q1 FY2023 | Mar 31, 2023 | -$7.89M | – |
| Q4 FY2022 | Dec 31, 2022 | -$6.36M | – |
| Q3 FY2022 | Sep 30, 2022 | -$9.02M | – |
| Q2 FY2022 | Jun 30, 2022 | -$8.36M | – |
| Q1 FY2022 | Mar 31, 2022 | -$7.79M | – |
| Q4 FY2021 | Dec 31, 2021 | -$9.56M | – |
| Q3 FY2021 | Sep 30, 2021 | -$5.41M | – |
| Q2 FY2021 | Jun 30, 2021 | -$4.92M | – |
| Q1 FY2021 | Mar 31, 2021 | -$2.85M | – |
| Q4 FY2020 | Dec 31, 2020 | -$2.63M | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.96M | – |
| Q2 FY2020 | Jun 30, 2020 | -$3.30M | – |
| Q1 FY2020 | Mar 31, 2020 | -$2.48M | – |
| Q4 FY2019 | Dec 31, 2019 | -$5.43M | – |
| Q3 FY2019 | Sep 30, 2019 | -$5.63M | – |
| Q2 FY2019 | Jun 30, 2019 | -$3.63M | – |
| Q1 FY2019 | Mar 31, 2019 | -$4.29M | – |
| Q4 FY2018 | Dec 31, 2018 | -$5.59M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.71M | – |
| Q2 FY2018 | Jun 30, 2018 | -$4.19M | – |
| Q1 FY2018 | Mar 31, 2018 | -$3.10M | – |
| Q4 FY2017 | Dec 31, 2017 | -$3.81M | – |
| Q3 FY2017 | Sep 30, 2017 | -$2.15M | – |
| Q2 FY2017 | Jun 30, 2017 | -$2.33M | – |
| Q1 FY2017 | Mar 31, 2017 | -$1.56M | – |
| Q4 FY2016 | Dec 31, 2016 | -$4.57M | – |
| Q3 FY2016 | Sep 30, 2016 | -$2.14M | – |
See a number that looks wrong?